Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study
Entheon Biomedical (ENBI) initiated a ketamine study on treatment resistant depression in partnership with Wavepaths. It will monitor brain activity with EEG while assessing the impact of Wavepaths’ personalized music technology.